Aurora Cannabis (ACB) vs Definium Therapeutics (DFTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Definium Therapeutics (DFTX) has outperformed Aurora Cannabis (ACB) over the past year, gaining 193.1% versus a loss of 27.7%. Over five years, DFTX leads with a -0.5% price change compared with -93.7% for ACB. Definium Therapeutics is the larger company by market cap ($4.71 billion vs $282.4 million), about 16.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACB | DFTX |
|---|---|---|
| Share price | $4.46 | $35.09 |
| Market cap | $282.36M | $4.71B |
| 1-day change | -2.83% | -1.49% |
| YTD return | +5.69% | +162.06% |
| 1-year return | -27.71% | +193.15% |
| 5-year return | -93.66% | -0.45% |
| EPS (TTM) | $-0.59 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-183.79M |
| 52-week high | $6.67 | $49.70 |
| 52-week low | $2.56 | $10.47 |
| Distance from 52-week high | -33.08% | -29.40% |
| Analyst consensus | buy | none |
| Avg. price target upside | — | +104.19% |
| Average volume | 1.36M | 2.15M |
| Shares outstanding | 63.31M | 134.37M |
| Employees | 1,028 | 105 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Definium Therapeutics is about 16.7 times larger than Aurora Cannabis by market value ($4.71B vs $282.36M).
- DFTX has outperformed ACB by 220.9 percentage points over the past year.
- The two companies sit in different sectors: Aurora Cannabis in Healthcare and Definium Therapeutics in Health Care.
About Aurora Cannabis
ACB stock →Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,028 employees
About Definium Therapeutics
DFTX stock →Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 105 employees
ACB vs DFTX FAQ
Which is bigger, Aurora Cannabis or Definium Therapeutics?
Definium Therapeutics (DFTX) is larger, with a market capitalization of $4.71B compared with $282.36M for Aurora Cannabis (ACB).
Which stock has performed better over the past year, ACB or DFTX?
DFTX returned +193.15% over the past 12 months, compared with -27.71% for ACB (price return, excluding dividends). Past performance does not predict future results.
Are Aurora Cannabis and Definium Therapeutics in the same industry?
No. Aurora Cannabis is in the Healthcare sector, while Definium Therapeutics is in Health Care.